Synergistic Gene Therapy System for Mucopolysaccharidosis Type I

A novel system integrating blockchain, AI, IoT, and gene therapy to provide personalized treatment for mucopolysaccharidosis type I, enhancing efficacy and reducing treatment costs.

Mucopolysaccharidosis type I (MPS I) is a debilitating genetic disorder with limited treatment options. The original patent disclosed a method for treating MPS I using gene therapy, but it has limitations in terms of treatment efficacy, patient monitoring, and data management. The present inventive concept addresses these limitations by combining gene therapy with blockchain, AI, and IoT technologies to create a more effective, efficient, and personalized treatment system.

The synergistic gene therapy system consists of several components: (1) a blockchain-based decentralized database for tracking patient treatment outcomes, ensuring data integrity and security; (2) a machine learning algorithm for predicting optimal gene therapy regimens based on patient-specific characteristics; (3) IoT-enabled sensors for real-time monitoring of treatment efficacy; (4) AI-designed gene therapy vectors with site-specific integration into the albumin locus; and (5) a system for optimizing gene therapy regimens using data from multiple sources. This integrated system enables personalized treatment, improves treatment outcomes, and reduces costs.

The new claims introduce the novel combination of blockchain, AI, IoT, and gene therapy, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more effective and efficient treatment system for MPS I.

Alternative embodiments of the inventive concept could include the use of different blockchain platforms, AI algorithms, or IoT sensors. Additionally, the system could be adapted for treating other genetic disorders or expanded to include additional features, such as telemedicine integration or patient engagement platforms.

The synergistic gene therapy system has significant commercial potential in the biotechnology and pharmaceutical industries, with a target market of patients with MPS I and other genetic disorders. The system's ability to provide personalized treatment, improve treatment outcomes, and reduce costs makes it an attractive solution for healthcare providers and payers.